Strategic Global Market Access: The Role of Health-Technology Assessments in Navigating Access Barriers for Biopharmaceuticals

Global advancements in the development of biologics and advanced-therapy medicinal products (ATMPs) are transforming the world of medicine through the approval of novel breakthrough therapies that treat previously uncurable diseases. However, many barriers stand between therapies and widespread access. Some of the most prominent hurdles are high treatment costs, which pose a significant obstacle for patients and other stakeholders, including employers, government-funded healthcare programs, commercial payers, healthcare providers, and drug manufacturers. Shared goals across the industry include improved affordability and accessibility to address health inequities and quality of life (QoL) for patients worldwide.

To read more, click here